Scientific publications
A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?
Silvia Gómez-Zorrilla 1 2 , Federico Becerra-Aparicio 3 4 , Inmaculada López Montesinos 5 3 , Enrique Ruiz de Gopegui 3 6 , Inmaculada Grau 3 7 , Vicente Pintado 3 8 , Belén Padilla 3 9 , Natividad Benito 10 , Lucía Boix-Palop 11 , Maria Carmen Fariñas 3 12 , María Peñaranda 13 , Maria Rocío Gamallo 14 , Jose Antonio Martinez 3 15 , Elena Morte-Romea 16 , Jose Luis Del Pozo 3 17 , Xavier Durán-Jordá 18 , Jazmin Díaz-Regañón 19 , Diego López-Mendoza 19 , Rafael Cantón 3 4 , Antonio Oliver 3 6 , Patricia Ruiz-Garbajosa 3 4 , Juan Pablo Horcajada 20 21 , REIPI/GEIRAS-GEMARA SEIMC ITUBRAS-2 Group
Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes.
Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract.
The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality.
Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups.
In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77-6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27-6.44) and Charlson index (aOR 1.11; 95% CI 1.01-1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40-0.93) were less likely to present clinical cure.
Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure.
CITATION Infect Dis Ther. 2021 Oct 9. doi: 10.1007/s40121-021-00537-0
Our authors
